PMID- 26889981
OWN - NLM
STAT- MEDLINE
DCOM- 20161230
LR  - 20161231
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 16
IP  - 3
DP  - 2016
TI  - Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high 
      Gleason score and biochemical recurrence after laparoscopic radical 
      prostatectomy.
PG  - 351-8
LID - 10.3233/CBM-160573 [doi]
AB  - OBJECTIVES: This study was aimed to explore Cdc20 expression and its correlation 
      with clinicopathological characteristics and biochemical recurrence (BCR) after 
      laparoscopic radical prostatectomy (LRP) in clinically localized prostate cancer 
      (PCa). METHODS: Cdc20 expression was examined by immunohistochemistry in 166 
      cases, including 60 cases of benign hyperplasia of prostate (BPH) patients 
      treated by transurethral resection and 106 cases of consecutive PCa patients 
      treated by LRP without neoadjuvant therapy in a single Chinese institution. The 
      correlation with clinicopathological features and the predictive value for BCR 
      were statistically analyzed. RESULTS: Cdc20 expression was detected in 52 (86.7%) 
      BPH and 97 (91.5%) PCa samples, which was statistically insignificant (P= 0.675). 
      The rate of patients with high expression of Cdc20 was 21.7% in BPH and 37.7% in 
      PCa (P= 0.033). A correlation was revealed between Cdc20 expression and 
      postoperative Gleason scores (P= 0.046), positive surgical margin (P< 0.001). 
      BCR-free survival was significantly lower in patients with high Cdc20 expression 
      than those with low Cdc20 expression (P= 0.018). Univariate analysis indicated 
      pTstage, post operative Gleason score, seminal vesicle invasion, lymph node 
      invasion, surgical margin and Cdc20 expression significantly influenced BCR. 
      Multivariate analysis revealed that postoperative Gleason score, seminal vesicle 
      invasion, lymph node invasion, surgical margin and Cdc20 expression were 
      independent predictors for BCR. After stratified by Gleason score and surgical 
      margin status, Cdc20 expression and lymph node invasion remained significant in 
      Cox regression analysis. CONCLUSIONS: Overexpression of Cdc20 may serve as an 
      independent predictor for BCR in patients of clinically localized PCa undergoing 
      LRP without neoadjuvant therapy.
FAU - Mao, Yunhua
AU  - Mao Y
AD  - Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Li, Ke
AU  - Li K
AD  - Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Lu, Li
AU  - Lu L
AD  - Department of Urology, The Sixth Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Si-Tu, Jie
AU  - Si-Tu J
AD  - Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Lu, Minhua
AU  - Lu M
AD  - Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
FAU - Gao, Xin
AU  - Gao X
AD  - Department of Urology, The Third Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cdc20 Proteins)
RN  - 156288-95-8 (CDC20 protein, human)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/biosynthesis/blood
MH  - Cdc20 Proteins/*biosynthesis
MH  - Humans
MH  - Laparoscopy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*pathology
MH  - Prostate/*pathology/surgery
MH  - Prostate-Specific Antigen/blood
MH  - Prostatectomy
MH  - Prostatic Hyperplasia/*pathology/surgery
MH  - Prostatic Neoplasms/*pathology/surgery
OTO - NOTNLM
OT  - Prostatic neoplasms
OT  - biochemical recurrence
OT  - cell division cycle 20
OT  - radical prostatectomy
EDAT- 2016/02/19 06:00
MHDA- 2016/12/31 06:00
CRDT- 2016/02/19 06:00
PHST- 2016/02/19 06:00 [entrez]
PHST- 2016/02/19 06:00 [pubmed]
PHST- 2016/12/31 06:00 [medline]
AID - CBM573 [pii]
AID - 10.3233/CBM-160573 [doi]
PST - ppublish
SO  - Cancer Biomark. 2016;16(3):351-8. doi: 10.3233/CBM-160573.